CN104984372B - 放射性缀合法 - Google Patents

放射性缀合法 Download PDF

Info

Publication number
CN104984372B
CN104984372B CN201510440109.1A CN201510440109A CN104984372B CN 104984372 B CN104984372 B CN 104984372B CN 201510440109 A CN201510440109 A CN 201510440109A CN 104984372 B CN104984372 B CN 104984372B
Authority
CN
China
Prior art keywords
peptide
cys
gly
thr
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201510440109.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104984372A (zh
Inventor
B.因德雷福尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1020314.9A external-priority patent/GB201020314D0/en
Priority claimed from GBGB1106593.5A external-priority patent/GB201106593D0/en
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of CN104984372A publication Critical patent/CN104984372A/zh
Application granted granted Critical
Publication of CN104984372B publication Critical patent/CN104984372B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/02—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201510440109.1A 2010-12-01 2011-12-01 放射性缀合法 Active CN104984372B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1020314.9A GB201020314D0 (en) 2010-12-01 2010-12-01 Apoptosis pet imaging agents
GB1020314.9 2010-12-01
US201161476805P 2011-04-19 2011-04-19
US61/476805 2011-04-19
GBGB1106593.5A GB201106593D0 (en) 2011-04-19 2011-04-19 Radioconjugation method
GB1106593.5 2011-04-19
CN201180057989.4A CN103269725B (zh) 2010-12-01 2011-12-01 放射性缀合法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180057989.4A Division CN103269725B (zh) 2010-12-01 2011-12-01 放射性缀合法

Publications (2)

Publication Number Publication Date
CN104984372A CN104984372A (zh) 2015-10-21
CN104984372B true CN104984372B (zh) 2018-11-09

Family

ID=45063153

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180057989.4A Active CN103269725B (zh) 2010-12-01 2011-12-01 放射性缀合法
CN201510440109.1A Active CN104984372B (zh) 2010-12-01 2011-12-01 放射性缀合法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201180057989.4A Active CN103269725B (zh) 2010-12-01 2011-12-01 放射性缀合法

Country Status (12)

Country Link
US (2) US9493504B2 (https=)
EP (2) EP2646060B1 (https=)
JP (1) JP6231882B2 (https=)
KR (1) KR20130119957A (https=)
CN (2) CN103269725B (https=)
AU (1) AU2011334881A1 (https=)
BR (1) BR112013013283A2 (https=)
CA (1) CA2819347A1 (https=)
ES (2) ES2675102T3 (https=)
MX (1) MX2013006202A (https=)
RU (1) RU2013122649A (https=)
WO (1) WO2012072736A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2819347A1 (en) * 2010-12-01 2012-06-07 Ge Healthcare Limited Radioconjugation method
GB201314936D0 (en) * 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322451D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Purification method and compositions
GB201322456D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
AU2019212849B2 (en) * 2018-01-26 2024-02-29 F. Hoffmann-La Roche Ag Radiolabelled oligonucleotides and process for their preparation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040662A2 (en) * 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
GB0305704D0 (en) * 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
CA2556169C (en) * 2004-01-29 2011-11-22 Andrew Lees Use of amino-oxy functional groups in the preparation of vaccines
GB0420365D0 (en) 2004-09-14 2004-10-13 Hammersmith Imanet Ltd Radiolabelled insulin
GB0420344D0 (en) 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
WO2008075966A2 (en) 2006-12-18 2008-06-26 Ge Healthcare As Synthesis of a radiofluorinated peptide using photolabile protecting groups
US8216548B2 (en) * 2006-12-28 2012-07-10 Ge Healthcare As Radiofluorination methods
US8545809B2 (en) * 2007-01-11 2013-10-01 Immunomedics, Inc. Methods and compositions for improved 18F labeling of proteins, peptides and other molecules
US20080274046A1 (en) * 2007-02-20 2008-11-06 Christian Prenant Radiolabelling
GB0803477D0 (en) * 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method
CA2819347A1 (en) * 2010-12-01 2012-06-07 Ge Healthcare Limited Radioconjugation method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Development of Novel 68Ga- and 18F-Labeled GnRH-I Analogues with High GnRHR-Targeting Efficiency";Margret Schottelius等;《Bioconjugate Chem.》;20080428;第2008卷(第19期);标题，摘要，第1259页左栏第4-5段，第1265页左栏第4段 *

Also Published As

Publication number Publication date
EP3395373B1 (en) 2022-10-19
CN103269725B (zh) 2015-09-23
EP2646060B1 (en) 2018-05-30
RU2013122649A (ru) 2015-01-10
CA2819347A1 (en) 2012-06-07
CN104984372A (zh) 2015-10-21
ES2929507T3 (es) 2022-11-29
EP2646060A2 (en) 2013-10-09
WO2012072736A3 (en) 2012-10-18
JP6231882B2 (ja) 2017-11-15
US9493504B2 (en) 2016-11-15
MX2013006202A (es) 2013-07-29
EP3395373A1 (en) 2018-10-31
AU2011334881A1 (en) 2013-06-06
KR20130119957A (ko) 2013-11-01
JP2014500883A (ja) 2014-01-16
US20130259803A1 (en) 2013-10-03
ES2675102T3 (es) 2018-07-06
WO2012072736A2 (en) 2012-06-07
CN103269725A (zh) 2013-08-28
US20170044080A1 (en) 2017-02-16
BR112013013283A2 (pt) 2016-11-22

Similar Documents

Publication Publication Date Title
CN104984372B (zh) 放射性缀合法
US20210330824A1 (en) Purification method and compositions
CN105848687B (zh) 放射性示踪剂组合物和方法
US20160022847A1 (en) Radiotracer Compositions
US10548995B2 (en) Radiolabelling method
CN104797273A (zh) 用于放射氟化的18f-标记的醛组合物
HK1226050A1 (en) Purification method and compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant